NTRA - Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value
- Natera, Inc. is a leading global diagnostics company developing cell-free DNA ("cfDNA") tests focusing on women's health, oncology, and organ health.
- Natera's current diagnostics product offering includes ~10 different unique tests with most of the product revenues coming from the sale of the Panorama and HCS tests.
- Natera is in a strong financial position as of 1Q 2021 with 2-3 years of funding based on cash of $654M and a TTM cash burn of -$244M.
- Natera has maintained strong revenue growth in 2020 reaching $391M (+29% y/y) driven by sales of Panorama and HCS tests with management guidance for 2021's revenues expected to reach ~$562.5M (+44% y/y).
- In summary, the author projects Natera, Inc. as a "buy" at a 2-year Wall Street price target of $137 (+21% upside).
For further details see:
Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value